Drug Delivery Systems

Nanotechnology’s Role in Fighting Cancer

One of the predominant features of nano-materials is an extremely high surface area. Emerging Science joins Chris Landry, professor of chemistry at the University of Vermont, as he describes how nanotechnology applications are improving the efficacy of cancer drugs by delivering more medicine to patients.

1998 Lemelson-MIT prize winner Robert S. Langer

Dr. Robert Langer was awarded the 1998 Lemelson-MIT Prize for being one of history’s most prolific inventors in medicine. His breakthroughs in controlled drug delivery have prolonged lives and eased the suffering of millions.

Nanotechnology and drug delivery

Nanotechnology and drug delivery

Approximately 99 per cent of medicinal molecules don’t reach their targets and subsequently, stay in the body of the patient. As these molecules can sometimes be very toxic – particularly in the case of those designed to target cancers – research is being undertaken into more effective ways of safely transporting and delivering drugs.

A challenge for nanotechnology in this research is to create a device which can carry a drug payload to it’s target, be monitored throughout it’s journey and deliver, without being attacked and destroyed by the body’s natural defences. This calls for something which possesses stealth design characteristics and a plausible device is described here in this movie.

This is one of a selection of intriguing movies which are available for free download from the EPSRC Nanotechnology Image Library at : http://www.nanoscience.dept.shef.ac.u…

You may also be interested in navigating to the “Soft Machines” site belonging to Professor Richard Jones – who features in this movie – for up-to-date discourse on all things nano. Here’s the link : http://www.softmachines.org/wordpress/

BME Women from Yale

Biomedical Engineer Receives L’Oreal Women in Science Fellowship

Source from >http://www.eurekalert.org/pub_releases/2009-05/yu-nhp050109.php        

A biomedical engineer from Yale University received one of five 2007 L’Or?al USA Fellowships for Women in Science and a grant of $40,000 at a ceremony in New York yesterday. Kim Woodrow’s research at the university in New Haven, Conn., involves using bioactive peptides to engineer biodegradable nanoparticles that can deliver drugs to specific cells and treat infectious diseases and cancer. This combination of molecular biology and nanotechnology will likely translate into new technology for imaging and treating diseases, L’Or?al said. Also receiving 2007 fellowships and $40,000 grants were earth scientist and geochemist Jaime Barnes of the University of New Mexico; neuroscientist Sarah Clinton of the University of Michigan, Ann Arbor; physical chemist Maria Krisch of the University of California, Irvine; and oceanographer Julie Huber of the Marine Biological Laboratory in Woods Hole, Mass.

IMAGE: This is Kim Woodrow from Yale University.Click here for more information. 

Nanotechnology holds promise for STD drug delivery

New Haven, Conn. — Yale researchers describe a breakthrough in safe and effective administration of potential antiviral drugs — small interfering RNA (siRNA) molecules that silence genes — the first step in development of a new kind of treatment for sexually transmitted diseases (STDs). The work is reported May 4 as an advance online publication of Nature Materials.

“RNA interference is a promising approach for prevention and treatment of human disease,” said lead author Kim Woodrow, Yale postdoctoral fellow in Yale’s School of Engineering & Applied Science. “We wanted to develop a new strategy of delivering siRNAs with a FDA-approved material.”

As their name suggests, siRNAs interfere and knock out the function of genes in higher organism as well as in microbes that may cause STDs. The researchers designed siRNAs to target a gene expressed widely in the lining of the female mouse reproductive tract, in this proof-of-principle work.

Using densely-loaded nanoparticles made of a biodegradable polymer known as PLGA, the researchers created a stable “time release” vehicle for delivery of siRNAs to sensitive mucosal tissue like that of the female reproductive system.

They found that the particles, loaded with the drug agent, moved effectively in two important ways, penetrating to reach cells below the surface of the mucosa and distributing throughout the vaginal, cervical, and uterine regions. Furthermore, the siRNAs stayed in the tissues for at least a week and knockdown of gene activity lasted up to 14 days.

While past work has focused on delivery of siRNAs with liposomes, bubble-like carriers made of phospholipids similar to those found in cell membranes, liposomes are potentially more toxic to the mucosal tissues and are unable to provide sustained release. In the current work, the researchers demonstrated that PLGA nanoparticles were safer than the best current lipid vehicles.


IMAGE: Distribution of nanoparticles seen by fluorescence throughout mouse reproductive tract.Click here for more information. 

Gene interference therapy is moving rapidly from basic research to application. The PLGA packaging these researchers chose is already approved as safe and non-toxic by the FDA, speeding the path to clinical trials for infectious agents such as HPV and HIV.

“Before human clinical testing can begin, our next step in research will be to test this approach directly in disease models – for example in the HIV model mice that have an immune system genetically identical to humans,” said senior author W. Mark Saltzman, the Goizueta Foundation Professor of Biomedical Engineering & Chemical Engineering.

This approach holds promise for global health and the ability of people to self–apply antimicrobial treatments. Woodrow said, “It is safe and effective and much easier than getting an injection of vaccine.”

Advances in drug delivery systems


Innovative pharmaceutical treatments require innovative methods of administration.

For most of the industry’s existence, pharmaceuticals have primarily consisted of simple, fast-acting chemical compounds that are dispensed orally (as solid pills and liquids) or as injectables. During the past three decades, however, formulations that control the rate and period of drug delivery (i.e., time-release medications) and target specific areas of the body for treatment have become increasingly common and complex. Because of researchers’ ever-evolving understanding of the human body and the explosion of new and potential treatments resulting from discoveries of bioactive molecules and gene therapies, pharmaceutical research hangs on the precipice of yet another great advancement. However, this next leap poses questions and challenges to not only the development of new treatments but also the mechanisms with which to administer them.

The current methods of drug delivery exhibit specific problems that scientists are attempting to address. For example, many drugs’ potencies and therapeutic effects are limited or otherwise reduced because of the partial degradation that occurs before they reach a desired target in the body. Once ingested, time-release medications deliver treatment continuously, rather than providing relief of symptoms and protection from adverse events solely when necessary. Further, injectable medications could be made less expensively and administered more easily if they could simply be dosed orally. However, this improvement cannot happen until methods are developed to safely shepherd drugs through specific areas of the body, such as the stomach, where low pH can destroy a medication, or through an area where healthy bone and tissue might be adversely affected.

The goal of all sophisticated drug delivery systems, therefore, is to deploy medications intact to specifically targeted parts of the body through a medium that can control the therapy’s administration by means of either a physiological or chemical trigger. To achieve this goal, researchers are turning to advances in the worlds of micro- and nanotechnology. During the past decade, polymeric microspheres, polymer micelles, and hydrogel-type materials have all been shown to be effective in enhancing drug targeting specificity, lowering systemic drug toxicity, improving treatment absorption rates, and providing protection for pharmaceuticals against biochemical degradation. In addition, several other experimental drug delivery systems show exciting signs of promise, including those composed of biodegradable polymers, dendrimers (so-called star polymers), electroactive polymers, and modified C-60 fullerenes (also known as “buckyballs”).

Polymers, polymers, everywhere
The earliest drug delivery systems, first introduced in the 1970s, were based on polymers formed from lactic acid. Today, polymeric materials still provide the most important avenues for research, primarily because of their ease of processing and the ability of researchers to readily control their chemical and physical properties via molecular synthesis. Basically, two broad categories of polymer systems, both known as “microspheres” because of their size and shape, have been studied: reservoir devices and matrix devices. The former involves the encapsulation of a pharmaceutical product within a polymer shell, whereas the latter describes a system in which a drug is physically entrapped within a polymer network. Or, put differently, if a medication is analogous to a piece of solid chocolate, a reservoir device is like a wrapped Hershey’s Kiss, and a matrix device is like a chocolate chip cookie.

The release of medications from either category of polymer device traditionally has been diffusion-controlled. Currently, however, modern research is aimed at investigating biodegradable polymer systems. These drug deliverers degrade into biologically acceptable compounds, often through the process of hydrolysis, which subsequently leave their incorporated medications behind. This erosion process occurs either in bulk (wherein the matrix degrades uniformly) or at the polymer’s surface (whereby release rates are related to the polymer’s surface area). The degradation process itself involves the breakdown of polymers into lactic and glycolic acids. These acids are eventually reduced by the Kreb’s cycle to carbon dioxide and water, which the body can easily expel.

Early research into biodegradable systems focused on naturally occurring polymers (collagen, cellulose, etc.) but has recently moved into the area of chemical synthesis. Examples of such polymers include polyanhydrides, polyesters, polyacrylic acids, poly(methyl methacrylates), and polyurethanes. As a result of extensive experimentation with these materials, several key factors have emerged to help scientists design more highly degradable polymers. Specifically, a fast-degrading matrix consists of a hydrophilic, amorphous, low-molecular-weight polymer that contains heteroatoms (i.e., atoms other than carbon) in its backbone and is grown either stepwise or through condensation reactions. Therefore, varying each of these factors allows researchers to adjust the rate of matrix degradation and, subsequently, control the rate of drug delivery.

In addition to research on carrier systems composed of single polymeric networks, researchers are investigating the properties of block copolymers (networks formed through the joint polymerization of two or more different monomers). These supramolecular networks, when composed of cross-linked combinations of hydrophilic and hydrophobic monomers, are called polymer micelles, and they self-arrange in shell-like structures with their hydrophilic and hydrophobic ligands aligned on opposing sides; in an aqueous medium, the hydrophilic portions form the outer shell.

These micelles are only tens of nanometers in diameter and are thus ideally sized for enclosing individual drug molecules. Further, their hydrophilic outer shells help protect the cores and their contents from chemical attack by the aqueous medium in which they must travel. Finally, drug release is achieved via common polymer degradation mechanisms, with the specificity of the delivery (e.g., cell-specific drug targeting) controlled by the synthetic design. For example, micelles containing attached sugar-group ligands have been shown to specifically target glyco-receptors in cellular plasma membranes.

Most micelle-based delivery systems are formed from a poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide) triblock network or a polypeptide and poly(ethylene oxide) combination. The results of these and other micellizations have proved quite promising. For example, in one investigation, researchers at the University of Tokyo, led by Kazunori Kataoka, have investigated the use of micelles as a means of delivering doxorubicin (a hydrophobic anticancer agent). Preliminary results have shown that, when dosed intravenously, the system can withstand the body’s normal blood circulation and effectively deliver the medication to a solid cancerous tumor.

Other promising investigations into the use of polymer matrixes as drug transport devices have also been studied. For example, one method uses conducting, electroactive polymers as a medium-sensing, bioactive molecule-releasing system. Drug delivery with these conducting polymer membranes is achieved through the controlled ionic transport of counterions (dopants) in and out of the membranes. Specifically, redox reactions regulate the necessary electrochemical switching, thus allowing electrostatically entrapped, anionic dopants (such as the biological molecule ATP, which has been investigated for various cardiovascular therapies) to be either retained or released. In fact, initial studies involving a polypyrrole-based polymer membrane have proved quite promising, with results indicating that the drug delivery rate, chemical sensing, and electrochemical triggering can all be synthetically and precisely controlled.

Finally, recent research has shown that hydrogel-type materials can be used to shepherd various medications through the stomach and into the more alkaline intestine. Hydrogels are cross-linked, hydrophilic, three-dimensional polymer networks that are highly permeable to various drug compounds, can withstand acidic environments, and can be tailored to “swell”, thereby releasing entrapped molecules through their weblike surfaces. Depending on the gel’s chemical composition, different internal and external stimuli (e.g., changes in pH, application of a magnetic or electric field, variations in temperature, and ultrasound irradiation) may be used to trigger the swelling effect. Once triggered, however, the rate of entrapped drug release is determined solely by the cross-linking ratio of the polymer network.

During the past two decades, research into hydrogel delivery systems has focused primarily on systems containing polyacrylic acid (PAA) backbones (see box at right for an example). PAA hydrogels are known for their super-absorbency and ability to form extended polymer networks through hydrogen bonding. In addition, they are excellent bioadhesives, which means that they can adhere to mucosal linings within the gastrointestinal tract for extended periods, releasing their encapsulated medications slowly over time.

Looking to the horizon
Chemists, biochemists, and chemical engineers are all looking beyond traditional polymer networks to find other innovative drug transport systems. Two of the more interesting cutting-edge technologies involve the use of dendrimers (highly branched, globular, synthetic macromolecules) and modified buckyballs to deploy medications capable of providing targeted drug delivery.

Dendritic macromolecules make suitable carrier systems because their size and structure can be controlled simply by synthetic means, and they can easily be processed and made biocompatible and biodegradable. In addition, while they can be used to encapsulate individual small drug molecules in the manner of polymer micelles (a “unimolecular nanocapsule”, if you will), they can also serve as “hubs” onto which large numbers of drug molecules can be attached via covalent bonds. The practical result of this latter ability, distinct from the micelle-based systems, is that a single dendrimer may transport extremely high densities of drug molecules. To date, these delivery systems remain largely unexplored, but researchers have demonstrated the usefulness of attaching the anticancer agents 5-fluorouracil to polyaminoamine dendrimers and methotrexate to hydrazide-terminated dendrimers formed from poly(aryl ether).

A team of inorganic chemists led by Lon Wilson at Rice University in Houston, TX, where the C-60, soccer ball–shaped fullerene was first discovered, is studying metallofullerene materials (all-carbon fullerene cages that enclose metal ions) for various applications, including the treatment of cancer tumors. In this particular application, the goal is to use selected metallofullerenes to deliver radioactive atoms directly to diseased tissues. The hoped-for result is an increased therapeutic potency and a decreased adverse effect profile for radiation treatments. Fullerenes, in fact, are ideally suited for this goal because of their size and resistance to biochemical attack from within the body. Thus, radioactive atoms may readily be transported within the balls, and any fear of stray radiation damaging otherwise healthy tissue is minimized.

At present, the Wilson group has successfully shown that modified soluble metallofullerenes will preferentially bind to human bone while slowly being cleared from other tissues. (As an interesting side note, the systems may also have application as contrast agents for magnetic resonance imaging because of the presence of an unpaired electron that renders magnetic the as-synthesized metallofullerenes.)

A cursory review
The technologies described here obviously represent little more than the tip of the iceberg for the development of drug delivery systems, and few of these even extend beyond the realm of benchtop experimentation. Although these approaches are the focus of intense, ongoing research, other processes are also under consideration, including aerosol inhalation devices, transdermal methodologies, forced-pressure injectables, and biodegradable polymer networks designed specifically to transport new gene therapies. Many of these advances are at the very least predicated on the technologies just described.

The need for research into drug delivery systems extends beyond ways to administer new pharmaceutical therapies; the safety and efficacy of current treatments may be improved if their delivery rate, biodegradation, and site-specific targeting can be predicted, monitored, and controlled. From both a financial and a global health care perspective, finding ways to administer injectable-only medications in oral form and delivering costly, multiple-dose, long-term therapies in inexpensive, potent, and time-releasing or self-triggering formulations are also needed. The promise of administration methods that allow patients to safely treat themselves is as significant as any other health care development, particularly in developing countries where doctors, clean syringes, sterile needles, and sophisticated treatments are few and far between.

Further reading

  • Bodor, N. S. Chemical Aspects of Drug Delivery Systems; Karsa, D. R., Stephenson, R. A., Eds; Royal Society of Chemistry: London, 1996.
  • Eisenberg, A. Bioconjugate Chem. 1998, 9, 564.
  • Han, J. H., et al. J. Agric. Food Chem. 2000, 48, 5278.
  • Langer, R. Macromolecules 1996, 29, 5279.
  • Controlled Drug Delivery: Challenges and Strategies; Park, K., Ed.; American Chemical Society: Washington, DC, 1997.
  • Reynolds, J. R. J. Phys. Chem. B 2000, 104, 4080.
  • Wu, C. Science News 1999, 155, 292.

Source from>>http://pubs.acs.org/subscribe/journals/mdd/v04/i04/html/MDD04FeatureVogelson.html